TYRUKO

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, United Kingdom

Active ingredients

The drug TYRUKO contains one active pharmaceutical ingredient (API):

1 Natalizumab
UNII 3JB47N2Q2P - NATALIZUMAB

Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils.

Read about Natalizumab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TYRUKO Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AG03 Natalizumab L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 3047734
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1231745001
Country: FR Base de données publique des médicaments Identifier(s): 60779570
Country: IT Agenzia del Farmaco Identifier(s): 050762018
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1097837

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.